USA flag logo/image

An Official Website of the United States Government

SBIR Phase II:Nano-scale Engineering via Grid-scale Computing: Designing,…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
91026
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
0912414
Solicitation Year:
N/A
Solicitation Topic Code:
C7a
Solicitation Number:
N/A
Small Business Information
Parabon NanoLabs, Inc.
11260 Roger Bacon Drive Suite 406 Reston, VA 20190-5203
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: SBIR Phase II:Nano-scale Engineering via Grid-scale Computing: Designing, Optimizing and Manufacturing Cancer Therapeutics
Agency: NSF
Contract: 1026606
Award Amount: $500,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase II project will advance the development of new drug compounds for the treatment of glioma, which have been designed and constructed with an innovative combination of grid-powered, computer-aided design (CAD) software and DNA nano-fabrication technology. The compounds are self-assembling DNA nanostructures functionalized with molecular subcomponents for targeting and destroying malignant glioma (brain) tumors. Prognosis for glioma is poor because complete surgical resection is impossible and chemotherapy (being poorly selective) leads to collateral brain damage, hence treatments are needed that target and destroy glioma cells with high specificity. The broader impacts of this research are the societal benefits associated with improved disease outcomes through the creation of revolutionary new nano-pharmaceuticals. The Company's efforts under this project are focused initially on creating an effective treatment for glioma, but the Company's Essemblix platform has the potential to be used to create compounds for a wide variety of 
indications. The ability to "plug and play" at the molecular level, made possible 
by PNL's computational and nano-fabrication technology, opens the door to the deliberate design and development of entirely new types of pharmaceutical materials that could address indications across a vast and diverse number of pharmaceutical and 
biotechnology market segments.

Principal Investigator:

Steven L. Armentrout
7036899689
sarmentrout@parabon.com

Business Contact:

Steven L. Armentrout
7036899689
sarmentrout@parabon.com
Small Business Information at Submission:

Parabon NanoLabs
11260 Roger Bacon Drive Suite 406 Reston, VA 20190

EIN/Tax ID: 262194625
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No